Last reviewed 2026-04-22 · How we verify

Topical Sertaconazole 2%

Sertaconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.

Sertaconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Topical fungal infections (dermatophytes, Candida species, and other susceptible fungi), Tinea pedis, tinea corporis, tinea cruris, and cutaneous candidiasis.

At a glance

Mechanism of action

As an imidazole antifungal, sertaconazole binds to the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in fungi, blocking the conversion of lanosterol to ergosterol. This disrupts the integrity and permeability of the fungal cell membrane, leading to cell death. The topical formulation delivers high local concentrations to skin and nail infections while minimizing systemic exposure.

Approved indications

• Topical fungal infections (dermatophytes, Candida species, and other susceptible fungi)
• Tinea pedis, tinea corporis, tinea cruris, and cutaneous candidiasis

Common side effects

• Contact dermatitis
• Local irritation or burning
• Erythema
• Pruritus

Key clinical trials

• Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis (PHASE4)
• Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Topical Sertaconazole 2% CI brief — competitive landscape report
• Topical Sertaconazole 2% updates RSS · CI watch RSS
• Jinnah Postgraduate Medical Centre portfolio CI